Question 1

When does Novo Nordisk plan to launch Wegovy®pill in select markets?

Accepted Answer

Novo Nordisk says it will launch Wegovy®pill in select markets in the second half of 2026, and then bring it to additional select countries in the coming months.

Question 2

What cloud provider is Novo Nordisk partnering with for a co-innovation hub in London?

Accepted Answer

Novo Nordisk and Amazon Web Services (AWS) set up a co‑innovation hub in London, with AWS positioned as Novo Nordisk’s preferred cloud provider and strategic AI partner.

Question 3

What lawsuit did Novo Nordisk file against Eli Lilly and Company?

Accepted Answer

On 21 July 2026, Novo Nordisk filed a lawsuit in the US District Court for the District of New Jersey against Eli Lilly and Lilly USA, alleging federal and state false advertising and unfair competition related to direct-to-consumer ads for Mounjaro and Zepbound.

Question 4

What rating and price target did Deutsche Bank set for Novo Nordisk after second-quarter results described as an "unusual print" by Emmanuel Papadakis?

Accepted Answer

Deutsche Bank reiterated a Hold rating and kept/set a DKK 290 price target after analyst Emmanuel Papadakis described Novo Nordisk’s second-quarter results as an “unusual print”.

Question 5

Which countries did Novo Nordisk launch Wegovy®pill (oral semaglutide) in 2026?

Accepted Answer

Novo Nordisk launched Wegovy®pill (oral semaglutide) in the United Arab Emirates in 2026, described as the first country outside the United States to make the oral GLP‑1 weight‑loss therapy available.

Question 6

What is Novo Nordisk selling its Parkinson's cell therapy program to?

Accepted Answer

Novo Nordisk agreed to sell its Parkinson’s cell therapy program to U.S. startup Cellular Intelligence, with an equity stake by Novo Nordisk plus potential future milestone payments and royalties.

Timeline

Novo Nordisk

Novo Nordisk teams up with Amazon in AI drug discovery partnership

Investment bank stays on fence over Novo Nordisk after tepid results

Novo Nordisk sues Eli Lilly over GLP-1 ad claims

Novo Nordisk launches Wegovypill in the UAE

Novo Nordisk study finds two in five high‑risk cardiovascular patients have persistent inflammation

More in Pharma

Shield Therapeutics takes full US control of ACCRUFeR

hVIVO buys CRS Berlin in earnings-accretive deal

AstraZeneca's Tezspire hits primary endpoints in esophagitis trial

Health & Bio Today: Faron's cash pile doubles ahead of Phase 2b MDS trial, 4basebio, Eden Research

Health & Bio Today: Solvonis raises £1.3m for CNS pipeline, AstraZeneca, Nuformix, BSF Enterprise

Small Caps Today: Solvonis raises £1.3m for CNS pipeline, Tungsten West lands £71m UK Government backing, Eco Atlantic, Volex, Galileo Resources

Solvonis raises £1.3m to fund pipeline milestones

Nuformix names Tim Metcalfe as new Chairman

Tuesday's Morning Brief: Navitas upgrades Eco Atlantic's Falklands and South Africa targets, Volex, Chesnara, Tialis, AstraZeneca, Gulf Keystone

AstraZeneca prices €2.55bn four-tranche bond offering

Health & Bio Today: EDX Medical raises £2.7m for screening push, GSK double

Browse by Sector

Market reports

Energy & Resources

Financials

Technology

Healthcare

Industrials

Consumer